Chemomab Therapeutics (CMMB) PT Raised to $25 at Oppenheimer Aug 27, 2025 12:21PM
Chemomab (CMMB) Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis Jun 3, 2025 08:01AM
Chemomab Therapeutics (CMMB) Tops Q1 EPS by 0c May 15, 2025 05:15PM
Chemomab Therapeutics (CMMB) Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025 May 5, 2025 08:03AM
Chemomab Therapeutics (CMMB) Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases Apr 28, 2025 08:03AM


Mar 27, 2025 08:30AM Chemomab Therapeutics (CMMB) Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial
Mar 3, 2025 04:28PM Chemomab Therapeutics (CMMB) Tops Q4 EPS by 5c
Feb 19, 2025 07:00AM Chemomab Therapeutics (CMMB) Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug
Nov 14, 2024 07:02AM Chemomab Therapeutics (CMMB) Tops Q3 EPS by 7c
Oct 15, 2024 07:01AM Chemomab Therapeutics (CMMB) Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD
Aug 21, 2024 07:10AM Chemomab Therapeutics (CMMB) Tops Q2 EPS by 9c
Jul 26, 2024 07:01AM Chemomab Therapeutics (CMMB) Regains Compliance With Nasdaq Minimum Bid Price Requirement
Jul 25, 2024 07:38AM Chemomab Therapeutics (CMMB) Announces $10 Million Private Placement
Jul 25, 2024 07:01AM Chemomab Therapeutics (CMMB) Reports Positive Phase 2 Trial Results for CM-101
Jun 18, 2024 07:03AM Chemomab Therapeutics (CMMB) Announces New Publications Reinforcing the Clinical Potential of CM-101